Forbion is a leading venture capital firm based in the Netherlands, focused exclusively on life sciences. The firm invests in innovative biotech and biopharmaceutical companies across Europe and North America, supporting drug development from early discovery through clinical stages. Forbion manages multiple funds and works closely with entrepreneurs to build sustainable, high-impact healthcare companies. With deep sector expertise and an extensive international network, Forbion aims to bring transformative therapies to patients worldwide while generating strong returns for investors.

Capital under management
Approximately EUR 5 billion in assets under management.

Investment requirements and financing offer
Forbion invests in European and North American biopharma companies across all stages of development. Initial investments typically range from EUR 30–40 million initially (depends on deal type and inevstment strategy), with substantial follow-on capacity. Active board participation and a long-term partnership approach.

Industry focus
Biopharmaceuticals spanning all therapeutic areas, stages and modalities.

Portfolio and exits
Portfolio includes companies such as New Amsterdam Pharma, Dyne, Catalym, Pheon, Sitala, Verdiva, Beacon, Braveheart and other. Successful exits are mainly driven by M&A (~80%), with a minor proportion of IPOs on NASDAQ (~20%).

Memberships in networks/associations
Forbion is active in European and international life sciences networks and venture capital associations including the recently announced European Life Science Coalition which was launched in association with Invest Europe to mobilize public and private investment into Europe’s life sciences Venture Capital ecosystem. Forbion is collaborating with research institutes, pharmaceutical companies, and co-investment partners across Europe and the US.

Date of foundation / Number of employees
2006 / ~45

Contact information

E-Mail: info@forbion.com
Social Media: LinkedIn
X 
Web Address: https://forbion.com